The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ordóñez, José Luis, Amaral, Ana Teresa, Carcaboso, Angel M., Herrero-Martín, David, García-Macías, María del Carmen, Sevillano, Vicky, Alonso, Diego, Pascual-Pasto, Guillem, San-Segundo, Laura, Vila-Ubach, Monica, Rodrigues, Telmo, Fraile, Susana, Teodosio, Cristina, Mayo-Iscar, Agustín, Aracil, Miguel, Galmarini, Carlos María, Tirado, Oscar M., Mora, Jaume, de Álava, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662461/
https://www.ncbi.nlm.nih.gov/pubmed/26056084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662461/
https://www.ncbi.nlm.nih.gov/pubmed/26056084

Ejemplares similares